The therapeutic efficacy of antibodies can be substantially enhanced by conjugation of cytotoxic
compounds such as chemotherapeutics and particle-emitting radionuclides.[1] Intuitively …

Introduction We assessed the suitability of the radiolanthanide 155 Tb (t 1/2 = 5.32 days, E γ
= 87 keV (32%), 105 keV (25%)) in combination with variable tumor targeted biomolecules …

Untethered small‐scale robots have great potential for biomedical applications. However,
critical barriers to effective translation of these miniaturized machines into clinical practice exist…

The rapid degradation of neurotensin (NT) limits its clinical use in cancer imaging and therapy.
Thus, a new NT(8–13) pseudopeptide, NT-VIII, was synthesized. Some changes were …

INTRODUCTION: Bombesin, a neuropeptide with potential for breast and prostate tumor
targeting, is rapidly metabolized in vivo, and as a result, uptake in tumor xenografts in mice is …

Microbial transglutaminase (MTG) was stably solid‐phase immobilized on glass microbeads
by using a second‐generation dendronized polymer. Immobilized MTG enabled the …

Purpose Neurotensin (NT) and its high affinity receptor (NTR1) are involved in several
neoplastic processes. Thus, NT-based radiopharmaceuticals are potential tracers for targeted …

Neurotensin (NT) receptors in pancreatic and other neuroendocrine tumors are promising
targets for imaging and therapeutic purposes. Here, we report on the effect of distinct changes …

The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the
development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which …

Over the last decades, great strides were made in the development of novel implants for the
treatment of bone defects. The increasing versatility and complexity of these implant designs …